Pancreatic Cancer Research

ResearcherWenzhou UniversityNo recent work listed

Jiayu Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6976-4568; OpenAlex author ID A5107905736. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper

Papers 6

  1. Yap1-2 Isoform Is the Primary Mediator in TGF-β1 Induced EMT in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.649290↗
  2. An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Co-author DOI 10.3389/fcell.2020.00287↗
  3. Corrigendum: An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Co-author DOI 10.3389/fcell.2020.594589↗
  4. Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway. Co-author DOI 10.12659/msm.917625↗
  5. Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Co-author DOI 10.1038/s41598-018-33229-w↗
  6. Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.17701↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Meiyu Quan · 3 shared papers, 2020–2021 · strength 0.30
  2. Jin‐San Zhang · 3 shared papers, 2020–2021 · strength 0.30
  3. Yuxin Chen · 2 shared papers, 2018–2019 · strength 0.26
  4. Zhenkun Lou · 2 shared papers, 2020 · strength 0.19
  5. Qiang Guo · 2 shared papers, 2020 · strength 0.19
  6. Daniel D. Billadeau · 2 shared papers, 2020 · strength 0.19
  7. Chao Gao · 1 shared paper, 2021 · strength 0.11
  8. Wei Wang · 1 shared paper, 2020 · strength 0.09
  9. Li Ding · 1 shared paper, 2020 · strength 0.09
  10. Kaichun Wu · 1 shared paper, 2017 · strength 0.06
  11. Zhaoyan Qiu · 1 shared paper, 2017 · strength 0.06
  12. Gang Wang · 1 shared paper, 2017 · strength 0.06
  13. Jie Liang · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.